Jazz Pharmaceuticals PLC Zanidatamab KOL Transcript
Hello, and thank you for standing by. Welcome to the Zanidatamab KOL Investor Webcast. (Operator Instructions) Please be advised that today's conference is being recorded. It is now my pleasure to introduce Chairman and CEO, Bruce Cozadd.
Thank you, operator, and good evening, everyone. Earlier today, pivotal Phase IIb data from the HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2 amplified biliary tract cancers or BTC, were featured in an oral session at this year's Annual Meeting of the American Society of Clinical Oncology.
zanidatamab is one of several late-stage programs in our pipeline that we are advancing on behalf of patients in need of improved treatment options, and we're excited to share these impressive results with you today. I'd like to remind you that today's webcast includes forward-looking statements as outlined on Slide 2. These statements are subject to risks and uncertainties. If we refer to guidance, that's referring to our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |